| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5969156 | ORGANON | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
| US5686104 | ORGANON | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(9 years ago) | |
|
US5686104 (Pediatric) | ORGANON | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(8 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
|
US5969156 (Pediatric) | ORGANON | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
Liptruzet is owned by Organon.
Liptruzet contains Atorvastatin Calcium; Ezetimibe.
Liptruzet has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Liptruzet are:
- US5846966
- US5846966*PED
- US5686104
- US5686104*PED
- USRE42461
- US5969156*PED
- USRE42461*PED
- US5969156
Liptruzet was authorised for market use on 03 May, 2013.
Liptruzet is available in tablet;oral dosage forms.
Liptruzet can be used as for the treatment of primary hyperlipidemia, mixed hyperlipidemia or homozygous familial hypercholesterolemia.
The generics of Liptruzet are possible to be released after 25 April, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 03, 2016 |
Drugs and Companies using ATORVASTATIN CALCIUM; EZETIMIBE ingredient
Market Authorisation Date: 03 May, 2013
Treatment: For the treatment of primary hyperlipidemia, mixed hyperlipidemia or homozygous familial hypercholesterolemia
Dosage: TABLET;ORAL
LIPTRUZET family patents
